Scholarlink

Purpose <p>Surgery is the standard treatment for early-stage pulmonary neuroendocrine tumors (NETs); however, long-term prognostic data are limited. This study aimed to establish the long-term outcomes of surgically resected pulmonary NETs.</p> Methods <p>This study included 263 patients who underwent pulmonary resection between January, 1997 and December, 2019: 89 with small cell lung carcinoma (SCLC), 120 with large cell neuroendocrine carcinoma (LCNEC), 14 with atypical carcinoid (AC), and 40 with typical carcinoid (TC). We analyzed clinicopathological characteristics and long-term prognosis.</p> Results <p>The 5-year relapse-free survival (RFS) rates were 38.7%, 54.2%, 62.3%, and 85.0%, and the 10-year RFS rates were 24.5%, 39.8%, 20.8%, and 76.4% for SCLC, LCNEC, AC, and TC, respectively. All deaths from TC occurred more than 5&#xa0;years after surgery, whereas three of the four deaths from AC occurred after this period. Most patients with high-grade NETs had relapses within 3&#xa0;years after surgery, whereas patients with AC had relapses not only in the early phase but also in the late phase.</p> Conclusions <p>The long-term prognosis of AC is comparable to that of high-grade NETs, suggesting that its biological characteristics might be more closely related to high-grade NETs than to TC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long-term survival outcome after surgical resection of pulmonary neuroendocrine tumors

  • 期刊论文

  • 发表日期：

    2025年7月23日

查看全文
  • Eisuke Goto,
  • Keiju Aokage,
  • Kotaro Nomura,
  • Makoto Tada,
  • Yutaro Koike,
  • Tetsuro Taki,
  • Tomohiro Miyoshi,
  • Kenta Tane,
  • Joji Samejima,
  • Kenji Suzuki,
  • Genichiro Ishii,
  • Masahiro Tsuboi

摘要

Purpose

Surgery is the standard treatment for early-stage pulmonary neuroendocrine tumors (NETs); however, long-term prognostic data are limited. This study aimed to establish the long-term outcomes of surgically resected pulmonary NETs.

Methods

This study included 263 patients who underwent pulmonary resection between January, 1997 and December, 2019: 89 with small cell lung carcinoma (SCLC), 120 with large cell neuroendocrine carcinoma (LCNEC), 14 with atypical carcinoid (AC), and 40 with typical carcinoid (TC). We analyzed clinicopathological characteristics and long-term prognosis.

Results

The 5-year relapse-free survival (RFS) rates were 38.7%, 54.2%, 62.3%, and 85.0%, and the 10-year RFS rates were 24.5%, 39.8%, 20.8%, and 76.4% for SCLC, LCNEC, AC, and TC, respectively. All deaths from TC occurred more than 5 years after surgery, whereas three of the four deaths from AC occurred after this period. Most patients with high-grade NETs had relapses within 3 years after surgery, whereas patients with AC had relapses not only in the early phase but also in the late phase.

Conclusions

The long-term prognosis of AC is comparable to that of high-grade NETs, suggesting that its biological characteristics might be more closely related to high-grade NETs than to TC.